Miguel Haime
Harvard University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Miguel Haime.
JAMA | 2011
Steven Goldman; Gulshan K. Sethi; William L. Holman; Hoang Thai; Edward O. McFalls; Herbert B. Ward; Rosemary F. Kelly; Birger Rhenman; Gareth H. Tobler; Faisal G. Bakaeen; Joseph Huh; Ernesto R. Soltero; Mohammed M. Moursi; Miguel Haime; Michael D. Crittenden; Vigneshwar Kasirajan; Michelle Ratliff; Stewart Pett; Anand Irimpen; William Gunnar; Donald Thomas; Stephen E. Fremes; Thomas E. Moritz; Domenic J. Reda; Lynn Harrison; Todd H. Wagner; Yajie Wang; Lori Planting; Meredith Miller; Yvette Rodriguez
CONTEXT Arterial grafts are thought to be better conduits than saphenous vein grafts for coronary artery bypass grafting (CABG) based on experience with using the left internal mammary artery to bypass the left anterior descending coronary artery. The efficacy of the radial artery graft is less clear. OBJECTIVE To compare 1-year angiographic patency of radial artery grafts vs saphenous vein grafts in patients undergoing elective CABG. DESIGN, SETTING, AND PARTICIPANTS Multicenter, randomized controlled trial conducted from February 2003 to February 2009 at 11 Veterans Affairs medical centers among 757 participants (99% men) undergoing first-time elective CABG. INTERVENTIONS The left internal mammary artery was used to preferentially graft the left anterior descending coronary artery whenever possible; the best remaining recipient vessel was randomized to radial artery vs saphenous vein graft. MAIN OUTCOME MEASURES The primary end point was angiographic graft patency at 1 year after CABG. Secondary end points included angiographic graft patency at 1 week after CABG, myocardial infarction, stroke, repeat revascularization, and death. RESULTS Analysis included 733 patients (366 in the radial artery group, 367 in the saphenous vein group). There was no significant difference in study graft patency at 1 year after CABG (radial artery, 238/266; 89%; 95% confidence interval [CI], 86%-93%; saphenous vein, 239/269; 89%; 95% CI, 85%-93%; adjusted OR, 0.99; 95% CI, 0.56-1.74; P = .98). There were no significant differences in the secondary end points. CONCLUSION Among Veterans Affairs patients undergoing first-time elective CABG, the use of a radial artery graft compared with saphenous vein graft did not result in greater 1-year patency. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00054847.
The Journal of Thoracic and Cardiovascular Surgery | 2014
Harold L. Lazar; Ara Ketchedjian; Miguel Haime; Karl J. Karlson; Howard Cabral
OBJECTIVE This study was undertaken to determine whether topical vancomycin would further reduce the incidence of sternal infections in the presence of perioperative antibiotics and tight glycemic control. METHODS A total of 1075 consecutive patients undergoing cardiac surgery from December 2007 to August 2013 receiving topical vancomycin (2.5 g in 2 mL of normal saline) applied as a slurry to the cut edges of the sternum were compared with 2190 patients from December 2003 to November 2007 who did not receive topical vancomycin. All patients received perioperative antibiotics (cefazolin 2 g intravenously every 8 hours and vancomycin 1 g intravenously every 12 hours) on induction of anesthetic and continuing for 48 hours; and intravenous insulin infusions to maintain serum blood glucose level between 120 and 180 mg/dL. RESULTS Patients receiving topical vancomycin had less superficial sternal infections (0% vs 1.6%; P < .0001), deep sternal infections (0% vs 0.7%; P = .005), any type of sternal infection (0% vs 2.2%; P < .0001) and significantly less sternal infections of any type in patients with diabetes mellitus (0% vs 3.3%; P = .0004). CONCLUSIONS Topical vancomycin applied to the sternal edges, in conjunction with perioperative antibiotics and tight glycemic control, helps to eliminate wound infections in cardiac surgical patients.
Ultrasound in Medicine and Biology | 2009
James L. Rudolph; Farzaneh A. Sorond; Val E. Pochay; Miguel Haime; Patrick R. Treanor; Michael D. Crittenden; Viken L. Babikian
Carotid stenosis is a frequent coexisting condition in patients undergoing coronary artery bypass graft (CABG) surgery. The impact of carotid stenosis on cerebral perfusion is not fully understood. The purpose of this study was to determine the impact of carotid stenosis on cerebral blood flow velocity in patients undergoing CABG. Seventy-three patients undergoing CABG were prospectively recruited and underwent preoperative Duplex carotid ultrasound to evaluate the degree of carotid stenosis. Intraoperatively, transcranial Doppler ultrasound was used to record the mean flow velocity (MFV) within the bilateral middle cerebral arteries. In addition, during the period of cardiopulmonary bypass, regulators of cerebral hemodynamics such as hematocrit, partial pressure of carbon dioxide and temperature were recorded. The ipsilateral middle cerebral artery mean flow velocity was compared in arteries with and without carotid stenosis using a repeated measures analysis. Seventy-three patients underwent intraoperative monitoring during CABG and 30% (n=22) had carotid stenosis. Overall, MFV rose throughout the duration of CABG including when the patient was on cardiopulmonary bypass. However, there was no significant MFV difference between those arteries with and without stenosis (F=1.2, p=.21). Further analysis during cardiopulmonary bypass, demonstrated that hemodilution and partial pressure of carbon dioxide may play a role in cerebral autoregulation during CABG. Carotid stenosis did not impact mean cerebral blood flow velocity during CABG. The cerebrovascular regulatory process appears to be largely intact during CABG.
Journal of Cardiothoracic and Vascular Anesthesia | 2011
Kay B. Leissner; Venkatesh Srinivasa; Sascha S. Beutler; Robina Matyal; Rana Badr; Miguel Haime; Feroze Mahmood
Fig 1. LA dissection, left ventricle (LV), LVOT, and aorta (Ao) are visualized in the midesophageal long-axis view after the first AVR. The LA is compressed by the intramural hematoma (white arrows) leading to hypotension. The image is recorded in the process of re-establishing cardiopulmonary bypass. (Color version of figure is available online.)
Journal of Cardiac Surgery | 2012
Marisa Cevasco; Miguel Haime
Abstract This is a case of aortic valve endocarditis and leaflet perforation caused by Staphylococcus lugdunensis successfully treated with aortic valve replacement and antibiotics. We believe that the patients endocarditis may be related to the vasectomy he underwent two months prior to presentation, as S. lugdunensis is an integral component of normal skin flora of the lower abdomen and groin. We also suggest that whenever this organism is found in patients with endocarditis, early surgical treatment of the infected valve should be considered, as S. lugdunensis is an aggressive and virulent coagulase‐negative staphylococcus. (J Card Surg 2012;27:299‐300)
American Journal of Surgery | 2008
Laki Rousou; Michael D. Crittenden; Kristin B. Taylor; Nancy A. Healey; Stephen Gibson; Hemant S. Thatte; Miguel Haime; Shukri F. Khuri
BACKGROUND Myocardial acidosis during cardiac surgery and postoperative troponin I are markers of myocardial damage that have been shown to predict adverse outcomes. We investigated the relationship between troponin I and myocardial tissue pH, patient outcomes, and cost. METHODS Data were prospectively collected on 205 cardiac surgery patients. Troponin I was sampled upon arrival to the intensive care unit (ICU) and every 6 hours thereafter for 24 hours. The lowest pH encountered during aortic cross clamp (LpH) was related to postoperative troponin I on the multivariate level. Multivariate models were constructed to predict adverse events (AE) and cost. RESULTS LpH was an independent inverse determinant of postoperative troponin I (P = .0067). Troponin I and its interaction with LpH were multivariate predictors of AE (P = .0012; .0001;odds ratio = 6.9, 10.2, respectively). Troponin I independently predicts surgical ICU (SICU) cost (P = .0256). CONCLUSION Postoperative troponin I elevation reflects intraoperative myocardial acidosis and damage. The strong relationship between troponin I, AE, and cost indicates the damage incurred is clinically and economically relevant. Strategies to ameliorate intraoperative myocardial tissue acidosis will decrease troponin I release, subsequent AE, and associated costs.
Journal of the American College of Cardiology | 2012
Marco A. Zenati; Kousick Biswas; Annie Laurie Shroyer; Jacquelyn A. Quin; Miguel Haime; J. Michael Gaziano; Kristin Taylor; Deepak L. Bhatt
Failure of saphenous vein grafts (SVG) used in CABG is associated with increased rates of late major adverse cardiac events: these include death, myocardial infarction and need for revascularization. In the last 10 years endoscopic vein harvest (EVH) has become the preferred method of venous conduit
Expert Review of Cardiovascular Therapy | 2018
Miguel Haime; Robert R. McLean; Katherine E. Kurgansky; Maximilian Y. Emmert; Nicole Kosik; Constance Nelson; Michael Gaziano; Kelly Cho; David R. Gagnon
ABSTRACT Background: Saphenous vein grafts (SVGs) remain the most often used conduits for coronary bypass grafting (CABG). Progressive intimal hyperplasia contributes to vein-graft disease and vein-graft failure (VGF). We compared the impact of intraoperative preservation of SVGs in a storage solution (DuraGraft®) versus heparinized saline on VGF-related outcomes after CABG. Methods: From 1996 to 2004, 2436 patients underwent isolated CABG with ≥ 1 SVG. SVGs were consecutively treated with DuraGraft in 1036 patients (2001−2004) and heparinized saline in 1400 patients (1996−1999). Short- (< 30 days) and long-term (≥ 1000 days) outcomes were assessed using repeat revascularization (primary end point), and major adverse cardiac events (MACE) consisting of the composite of death, nonfatal myocardial infarction, or repeat revascularization. Results: Mean follow-up in the DuraGraft group was 8.5 ± 4.2 years and 9.9 ± 5.6 years in controls. Short-term event rates were low and generally did not differ between groups. DuraGraft was associated with a 45% lower occurrence of nonfatal myocardial infarction after 1000 days (hazard ratio 0.55, 95% CI 0.41−0.74; P < 0.0001). There was 35% and 19% lower long-term risk for revascularization (HR 0.65, 95% CI 0.44−0.97; P = 0.037) and MACE (HR 0.81, 95% CI 0.70−0.94; P = 0.0051), respectively, after DuraGraft. Mortality was comparable between both groups at 1, 5, and 10 years. There was no statistically significant association between DuraGraft exposure and time to death starting at 30 or 1000 days (HR 0.91, 95% CI 0.76−1.09; P = 0.29). Conclusion: In this study, intraoperative treatment of SVGs with DuraGraft was associated with a lower risk of long-term adverse events suggesting that efficient intraoperative SVG treatment may reduce VGF-related complications post-CABG. These data warrant randomized clinical trials to validate these findings.
Journal of the American College of Cardiology | 2010
Eric Russell; Victor Chien; Zain Khalpey; Marc P. Bonaca; Jayashri Aragam; Miguel Haime; Michael D. Crittenden
![Figure][1] ![Figure][1] [![Graphic][3] ][3] Transthoracic echocardiogram demonstrating an organized left ventricular (LV) thrombus. ![Figure][1] [![Graphic][4] ][4] Transthoracic echocardiogram demonstrating a mobile left ventricular (LV) thrombus. ![Figure][
Archive | 2016
Steven A. Goldman; Gulshan K. Sethi; William L. Holman; Hoang Thai; Edward O. McFalls; Herbert B. Ward; Rosemary F. Kelly; Birger Rhenman; Gareth H. Tobler; Faisal G. Bakaeen; Joseph Huh; Ernesto R. Soltero; Mohammed M. Moursi; Miguel Haime; Michael D. Crittenden; Vigneshwar Kasirajan; Michelle Ratliff; Stewart Pett